ERBB2 and neoplasm: In PTEN-deficient GC cells, the effect of anti-HER2 therapy on tumor growth inhibition and apoptosis is significantly reduced because PTEN deletion can activate the PI3K/AKT signaling pathway (152), thereby affecting the sensitivity of HER2-targeted therapy.